Biotech Values

[mcbio]

In my view it may be hard to tell anything much in either case. If I recall correctly (it's been a while) both CLDX and IMUC have quite a long period post-surgery where they do the analysis and prepare their vaccine. It was unclear to me how they counted patients that died in that period (or deteriorated enough so that they were never treated).

Start reading about halfway down of the article that pharmaclown posted in #msg-67864816 as I believe this addresses your post. Namely:

"The spokesperson added that "all patients start vaccination with rindopepimut after they finish chemoradiation, at about three months post diagnosis, and the company compares these outcomes with matched patients from historical databases who meet the same criteria. Again, this is unlike the ICT patients who routinely went six, and even up to 12 months following diagnosis without progression before starting vaccination. Since the ICT data take credit for the time before vaccination, the extra months in their data could very well reflect a selected patient population who would be expected to do well."

All told, seems like CLDX is taking a more conservative approach in reporting their data.